These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 2005390)
1. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. Peace DJ; Chen W; Nelson H; Cheever MA J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390 [TBL] [Abstract][Full Text] [Related]
2. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L] Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131 [TBL] [Abstract][Full Text] [Related]
3. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579 [TBL] [Abstract][Full Text] [Related]
4. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698 [TBL] [Abstract][Full Text] [Related]
5. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613 [TBL] [Abstract][Full Text] [Related]
6. Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1-23 of Ras protein. Yin L; Thomas C; Hsuan JJ; Stauss HJ Eur J Immunol; 1994 Sep; 24(9):1988-92. PubMed ID: 8088318 [TBL] [Abstract][Full Text] [Related]
7. Mutant ras epitopes as targets for cancer vaccines. Abrams SI; Hand PH; Tsang KY; Schlom J Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022 [TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13. La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949 [TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238 [TBL] [Abstract][Full Text] [Related]
10. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844 [TBL] [Abstract][Full Text] [Related]
11. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Gedde-Dahl T; Fossum B; Eriksen JA; Thorsby E; Gaudernack G Eur J Immunol; 1993 Mar; 23(3):754-60. PubMed ID: 8449222 [TBL] [Abstract][Full Text] [Related]
12. Detection of transforming ras proteins containing leucine at position 61 by a new mouse monoclonal antibody, ras(53-69)Leu61. Bizub D; Fischberg-Bender E; Heimer EP; Felix A; Skalka AM Cancer Res; 1989 Nov; 49(22):6425-31. PubMed ID: 2680065 [TBL] [Abstract][Full Text] [Related]
13. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse. Pullano TG; Sinn E; Carney WP Oncogene; 1989 Aug; 4(8):1003-8. PubMed ID: 2474786 [TBL] [Abstract][Full Text] [Related]
14. T cell recognition of a point mutation in the P21 Ras protein. Yin L; Lowe P; Stauss HJ Leukemia; 1993 Aug; 7 Suppl 2():S27-30. PubMed ID: 7689674 [TBL] [Abstract][Full Text] [Related]
15. Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules. Harris DP; Vordermeier HM; Arya A; Moreno C; Ivanyi J Immunology; 1995 Apr; 84(4):555-61. PubMed ID: 7790029 [TBL] [Abstract][Full Text] [Related]
16. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437 [TBL] [Abstract][Full Text] [Related]
17. Structural features of an antigen required for cellular interactions and for T cell activation in a MHC-restricted response. Langton BC; Mackewicz CE; Wan AM; Andria ML; Benjamini E J Immunol; 1988 Jul; 141(2):447-56. PubMed ID: 3260252 [TBL] [Abstract][Full Text] [Related]
18. Antibody to ras proteins in patients with colon cancer. Takahashi M; Chen W; Byrd DR; Disis ML; Huseby ES; Qin H; McCahill L; Nelson H; Shimada H; Okuno K Clin Cancer Res; 1995 Oct; 1(10):1071-7. PubMed ID: 9815896 [TBL] [Abstract][Full Text] [Related]
20. Functionally distinct agretopic and epitopic sites. Analysis of the dominant T cell determinant of moth and pigeon cytochromes c with the use of synthetic peptide antigens. Fox BS; Chen C; Fraga E; French CA; Singh B; Schwartz RH J Immunol; 1987 Sep; 139(5):1578-88. PubMed ID: 2442249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]